Wells Fargo analyst Jim Birchenough reiterates an Outperform rating on Fate Therapeutics with an $18 price target following review of the initial clinical results from an "off-the-shelf" NK-cell therapeutic from MD Anderson. The results validate Fate's own platform of NK-cell therapeutics, including off-the-shelf induced pluripotent stem cell derived FATE-NFT500 and engineered NK-CAR candidates like FATE-FT519 targeting CD19, Birchenough tells investors in a research note. He notes that MD Anderson presented a clinical update from a first-inpatient phase 1/2 trial of a cord blood derived natural killer cell CD19 chimeric antigen receptor.